Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs PPG Industries, Inc. (PPG) Price & Performance

Amgen, Inc.Trade
PPG Industries, Inc.Trade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs PPG Industries, Inc. — how do they compare? Amgen, Inc. trades at $413.01 (market cap $225.71B), while PPG Industries, Inc. trades at $115.82 (market cap $25.67B). The key difference: Amgen, Inc. is far larger — about 8.8× PPG Industries, Inc.'s market cap, and PPG Industries, Inc. pays the higher dividend (2.56%). Which is the better fit depends on your goals.

AMGNPPG
Market Cap
$225.71B$25.67B
Sector
HealthBasic Materials
52-Week High
$417.20$131.56
52-Week Low
$271.18$94.34
Enterprise Value
$269.02B$31.54B
Dividend Yield
2.42%2.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.

Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.

PPG Industries, Inc.

PPG Industries trades at $119.72, up 2.19% on the day, with a bullish technical outlook supported by moving averages. The company reported Q2 2026 sales growth of 7% year-over-year but missed EPS estimates. Recent dividend hikes and strong cash flow highlight financial health, while valuation ratios like a P/E of 17.18 suggest reasonable pricing. Analyst consensus is positive with a $129.17 price target.

Outlook remains favorable due to consistent dividend growth and operational strength, though risks include cost pressures and mixed earnings performance. The stock offers a balanced opportunity with upside potential from analyst targets, but investors should monitor margin trends and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About PPG Industries, Inc.

PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.

Read more on PPG